BeyondSpring Inc. announced updated efficacy results from a Phase 2 investigator-initiated study (303 Study) of a triple combination regimen involving pembrolizumab, plinabulin, and docetaxel. These results were presented at the 39th Society for Immunotherapy of Cancer's (SITC) Annual Meeting on November 8, 2024. The study focuses on patients with metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression after prior PD-1/PD-L1 inhibitor therapy.
The updated data from 30 patients demonstrated a median progression-free survival (PFS) of 8.6 months, which is more than double the historical control of 3-4 months for similar patient populations. Additionally, the study reported an impressive disease control rate of almost 90%. This efficacy is considered clinically meaningful for patients with this severe unmet medical need.
Plinabulin, a potent inducer of dendritic cell maturation, is believed to reinforce anti-tumor immune response and potentially overcome acquired immune checkpoint inhibitor resistance. The 303 Study is ongoing at Peking Union Medical College Hospital in Beijing, China, and intends to enroll a total of 47 patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.